Skip to content

TMJ NextGeneration(TM) Feasibility Study

A Feasibility Study of the Bruxoff™ Device to Assess EMG Activity in Subjects Diagnosed With Sleep Bruxism Using TMJ NextGeneration(TM)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02257320
Acronym
Bruxoff
Enrollment
10
Registered
2014-10-06
Start date
2014-11-30
Completion date
2015-05-31
Last updated
2015-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bruxism

Brief summary

The study is an open-label, prospective, single-center, non-randomized feasibility study of the Bruxoff(TM) device to identify EMG activity associated with bruxism, and to assess the impact of the TMJ NextGeneration(TM) device upon the occurrence of night-time bruxism events and incidence of migraines and headache in subjects diagnosed with sleep bruxism.

Detailed description

The study will be conducted at one study center in the U.S. Subjects will be enrolled in the trial for a period of 8 weeks. The study will consist of a screening phase lasting up to 2 weeks and a follow up treatment period lasting 8 weeks. Subjects will visit the dental clinic twice during the screening period, then five times during the treatment period.

Interventions

DEVICETMJ NextGeneration(TM)

The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.

Sponsors

Cardiox Corporation
CollaboratorINDUSTRY
TMJ Health
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subjects at least 18 years of age; 2. Subject has had a diagnosis of sleep bruxism; 3. Subject has been medically screened and diagnosed by a physician as having headaches and/or migraines; 4. Subject is willing to comply with the usage instructions for the Bruxoff device; 5. Is able to read and understand the ICF and has voluntarily provided written informed consent. 6. Subject is able to open their mouth at least 17 mm to be fitted for the TMJ NextGenerationTM device; 7. Male Subjects are willing to have a clean shaven face on the nights that the Bruxoff device will be used; 8. Subject agrees that when using the Bruxoff device to keep their cellular phone in another room.

Exclusion criteria

1. Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol; 2. Subject has any sleep disorder other than bruxism; 3. Subjects who have had direct trauma to the jaw; 4. Subjects who have had prior TMJ or ear surgery; 5. Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified; 6. Subjects with visible or congenital ear deformity as observed on targeted physical exam; 7. Subjects whose ear canal anatomy does not allow for fit of the study device; 8. Subjects who have a history of ear pain unrelated to TMJ; 9. Subjects who have a history of ear drainage in the past 6 months; 10. Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam; 11. Subject has experienced chronic pain (not including migraine pain) associated with sleep bruxism or TMD for more than six months; 12. Subject has a pacemaker.

Design outcomes

Primary

MeasureTime frame
Effectiveness of Bruxoff(TM) to measure EMG activity in bruxing subjects using the TMJ NextGeneration(TM) device.baseline and 8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026